Atrial Fibrillation and Subclinical Thyroid Dysfunction: Revisiting an Underrecognized Association - A Narrative Review
Abstract
Subclinical thyroid disease, defined by abnormal thyroid-stimulating hormone (TSH) with normal thyroid hormone levels, is common and may be an underrecognized contributor to atrial fibrillation (AF). This narrative review summarizes current evidence on how mild thyroid dysfunction influences AF risk and highlights practical implications for clinical management, drawing on mechanistic studies, observational epidemiology, and major guideline recommendations addressing subclinical hyperthyroidism, subclinical hypothyroidism, and cardiac rhythm outcomes. Subclinical hyperthyroidism shows a consistent association with increased AF risk. Proposed mechanisms include thyroid hormone–mediated changes in cardiac electrophysiology, increased adrenergic sensitivity, and atrial structural and electrical remodeling. Current American Thyroid Association and European Thyroid Association guidance supports treating higher-risk patients, particularly those older than 65 years or with cardiovascular comorbidities, when TSH is below 0.1 mIU/L. In contrast, evidence linking subclinical hypothyroidism to AF is weak. Although it has traditionally been associated with bradyarrhythmias, newer studies suggest a possible modest increase in AF risk. Treatment decisions for subclinical hypothyroidism are more nuanced, with the strongest consensus favoring therapy when TSH exceeds 10.0 mIU/L, while lower-level elevations generally require individualized assessment. Overall, subclinical thyroid dysfunction, especially subclinical hyperthyroidism, appears meaningfully related to AF risk, but important evidence gaps remain, including limited large-scale trial data showing that treatment prevents AF. Because subclinical thyroid disease and AF both increase with age, management should be individualized according to age, TSH severity, cardiovascular risk, and comorbidities.
Related
- Association Between Left Atrial Enlargement and Atrial Fibrillation in Elderly Patients with Left Ventricular Diastolic Dysfunction
- Subclinical Atrial Fibrillation
- The Impact of Subclinical Thyroid Dysfunction on Cerebrovascular Pathology: A Focus on Carotid Atherosclerosis and Stroke Severity
- Cumulative Burden of Prediabetes, Subclinical Myocardial Injury, and Myocardial Stress and Risk of Incident Atrial Fibrillation in Adults With Hypertension
- Gastrointestinal Side Effects of Low-Dose Oral Minoxidil in Patients with Alopecia: An Underrecognized Association.
BibTeX
@article{sapkota2026atrial,
title = {{Atrial Fibrillation and Subclinical Thyroid Dysfunction: Revisiting an Underrecognized Association - A Narrative Review}},
author = {Sachin Sapkota MD and Suchita Acharya MD and Kritick Bhandari MBBS and Aakriti Parajuli MD and Abinash Baniya MD and Jyothsna Goranti MD and Mehran Abolbashari MD and Barney Soskin MD},
journal = {Clinical Medicine Insights: Cardiology},
year = {2026},
month = oct,
doi = {10.1177/11795468261500860},
url = {https://doi.org/10.1177/11795468261500860},
note = {CC BY},
}
RIS
TY - JOUR
TI - Atrial Fibrillation and Subclinical Thyroid Dysfunction: Revisiting an Underrecognized Association - A Narrative Review
AU - Sachin Sapkota MD
AU - Suchita Acharya MD
AU - Kritick Bhandari MBBS
AU - Aakriti Parajuli MD
AU - Abinash Baniya MD
AU - Jyothsna Goranti MD
AU - Mehran Abolbashari MD
AU - Barney Soskin MD
PY - 2026
DA - 2026/10/24
JO - Clinical Medicine Insights: Cardiology
DO - 10.1177/11795468261500860
UR - https://doi.org/10.1177/11795468261500860
AB - Subclinical thyroid disease, defined by abnormal thyroid-stimulating hormone (TSH) with normal thyroid hormone levels, is common and may be an underrecognized contributor to atrial fibrillation (AF). This narrative review summarizes current evidence on how mild thyroid dysfunction influences AF risk and highlights practical implications for clinical management, drawing on mechanistic studies, observational epidemiology, and major guideline recommendations addressing subclinical hyperthyroidism, subclinical hypothyroidism, and cardiac rhythm outcomes. Subclinical hyperthyroidism shows a consistent association with increased AF risk. Proposed mechanisms include thyroid hormone–mediated changes in cardiac electrophysiology, increased adrenergic sensitivity, and atrial structural and electrical remodeling. Current American Thyroid Association and European Thyroid Association guidance supports treating higher-risk patients, particularly those older than 65 years or with cardiovascular comorbidities, when TSH is below 0.1 mIU/L. In contrast, evidence linking subclinical hypothyroidism to AF is weak. Although it has traditionally been associated with bradyarrhythmias, newer studies suggest a possible modest increase in AF risk. Treatment decisions for subclinical hypothyroidism are more nuanced, with the strongest consensus favoring therapy when TSH exceeds 10.0 mIU/L, while lower-level elevations generally require individualized assessment. Overall, subclinical thyroid dysfunction, especially subclinical hyperthyroidism, appears meaningfully related to AF risk, but important evidence gaps remain, including limited large-scale trial data showing that treatment prevents AF. Because subclinical thyroid disease and AF both increase with age, management should be individualized according to age, TSH severity, cardiovascular risk, and comorbidities.
SN - 1179-5468
ER -